NPPA caps trade margins on 137 anti-cancer drugs; revised MRPs of 1,364 anti-cancer formulations come into effect from 9 November 2026
Revised Maximum Retail Prices (MRPs) of anti-cancer medicines came into effect from 9 November 2026 after the National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on the MRP of 137 anti-cancer drugs, the Department said. The capping is based on the recommendations of an Expert Committee constituted by the Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare. According to the release, as on 8 November 2026, 85 pharmaceutical companies had reported revised MRPs for 1,364 anti-cancer formulations covering 121 drugs, with 679 brands reporting price reductions of more than 50%; the highest reported reduction in MRP is 96.45%. The Department estimates that, as a result of the price reductions, consumers will save ₹3,540.38 crore annually. Consumers can check the revised MRP printed on the medicine pack and verify prices through the Pharma Sahi Daam mobile app or the NPPA website; no chemist or hospital pharmacy can charge more than the revised MRP, and complaints of overcharging can be registered through the Pharma Jan Samadhan portal or the NPPA helpline 1800-111-255.
Drafted with AI assistance from the official PIB release linked above and checked against it by a second AI pass. Not line-edited by a human. Published by Mahesh Srivastava, who corrects any error you report.
Learning context
Capping trade margins on cancer medicines was tried as a pilot in 2019. A release of the Ministry of Chemicals and Fertilizers dated 28 February 2019 said the NPPA, in its meeting of 26 February 2019, invoked extraordinary powers in public interest under Para 19 of the Drugs (Prices Control) Order, 2013 to bring 42 non-scheduled anti-cancer drugs under price control through Trade Margin Rationalisation, by restricting the trade margin on the selling price (MRP) up to 30%. At that time 57 anti-cancer drugs were already under price control as scheduled formulations, and the 42 drugs were expected to cover 72 formulations and 355 brands as per data available with the NPPA. The revised prices were to come into effect from 8 March 2019. The release said the NPPA fixes prices of drugs placed in the National List of Essential Medicines under Schedule-I of the DPCO, and described the 2019 intervention as a pilot for 'Proof of Concept' for Trade Margin Rationalisation.
Check yourself: according to the February 2019 release, under which paragraph of the Drugs (Prices Control) Order, 2013 did the NPPA act, how many non-scheduled anti-cancer drugs did it bring under price control, and up to what level was the trade margin restricted?
Para 19; 42 non-scheduled anti-cancer drugs; up to 30% on the selling price (MRP).
Revision task: from this release, note the body that capped the trade margins and the ministry it falls under, the number of anti-cancer drugs covered, the date the revised MRPs took effect, the figures reported as on 8 November 2026 (companies, formulations, drugs, brands, highest reduction), the estimated annual saving, and where consumers can check prices or complain; from the note, the 2019 pilot's legal provision, the number of drugs and the trade margin limit. Remember that the annual saving is the release's estimate, and that the 2019 figures are not the 2026 ones.
Test yourself
Revised MRPs of anti-cancer formulations came into effect from 9 November 2026 after which body capped trade margins on the MRP of 137 anti-cancer drugs?
Show the answer
Answer: National Pharmaceutical Pricing Authority (NPPA)
The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, capped trade margins on the MRP of 137 anti-cancer drugs, and the revised MRPs came into effect from 9 November 2026. As on 8 November 2026, 85 pharmaceutical companies had reported revised MRPs for 1,364 anti-cancer formulations; the Department estimates annual savings to consumers of ₹3,540.38 crore.
Read the daily collection → · Editorial standards & corrections